Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) have earned an average recommendation of “Moderate Buy” from the seven ratings firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $14.25.

Several equities research analysts recently weighed in on OBIO shares. TD Cowen started coverage on shares of Orchestra BioMed in a research report on Wednesday, December 10th. They issued a “buy” rating on the stock. Wall Street Zen raised shares of Orchestra BioMed from a “strong sell” rating to a “hold” rating in a research note on Saturday, March 14th. Chardan Capital restated a “buy” rating and issued a $20.00 target price on shares of Orchestra BioMed in a report on Thursday, March 12th. Finally, Barclays upped their target price on shares of Orchestra BioMed from $11.00 to $12.00 and gave the company an “overweight” rating in a research report on Friday, January 9th.

Insiders Place Their Bets

In related news, insider David P. Hochman acquired 10,000 shares of the firm’s stock in a transaction on Friday, March 13th. The shares were acquired at an average cost of $4.29 per share, for a total transaction of $42,900.00. Following the completion of the transaction, the insider directly owned 1,086,467 shares in the company, valued at approximately $4,660,943.43. This trade represents a 0.93% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 8.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Orchestra BioMed

A number of institutional investors and hedge funds have recently modified their holdings of OBIO. Alyeska Investment Group L.P. bought a new position in shares of Orchestra BioMed during the 3rd quarter valued at approximately $3,386,000. Pathstone Holdings LLC bought a new stake in Orchestra BioMed in the third quarter worth $2,495,000. Vanguard Group Inc. lifted its position in Orchestra BioMed by 28.0% in the third quarter. Vanguard Group Inc. now owns 1,481,875 shares of the company’s stock worth $3,675,000 after buying an additional 324,558 shares during the last quarter. 683 Capital Management LLC purchased a new position in Orchestra BioMed during the fourth quarter worth $847,000. Finally, Marshall Wace LLP purchased a new position in Orchestra BioMed during the fourth quarter worth $712,000. Hedge funds and other institutional investors own 53.20% of the company’s stock.

Orchestra BioMed Price Performance

Shares of Orchestra BioMed stock opened at $4.76 on Thursday. The firm has a market cap of $278.56 million, a PE ratio of -4.21 and a beta of 0.56. The stock has a 50 day moving average of $4.19 and a 200 day moving average of $3.94. The company has a current ratio of 6.45, a quick ratio of 6.43 and a debt-to-equity ratio of 0.27. Orchestra BioMed has a 12 month low of $2.20 and a 12 month high of $5.42.

Orchestra BioMed (NASDAQ:OBIO) last issued its quarterly earnings data on Thursday, March 12th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.64. The business had revenue of $30.92 million for the quarter, compared to analysts’ expectations of $0.93 million. Orchestra BioMed had a negative return on equity of 184.17% and a negative net margin of 157.40%. On average, research analysts expect that Orchestra BioMed will post -1.66 EPS for the current fiscal year.

About Orchestra BioMed

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.